THURSDAY, Jan. 20, 2022 (HealthDay News) — A nomogram can assist clinicians in predicting cancer-specific survival in patients with primary intestinal non-Hodgkin lymphoma (PINHL), according to a study published online Dec. 20 in Cancer Management and Research.
Cuifen Zhang, from the Guangzhou University of Chinese Medicine, and colleagues developed and verified a novel nomogram to predict long-term cancer-specific survival in patients with PINHL. Data for a training cohort of 2,372 PINHL patients obtained from the Surveillance, Epidemiology, and End Results (SEER) database were analyzed. The nomogram was validated internally and externally in a SEER cohort with 1,014 patients and a First Affiliated Hospital of Guangzhou University of Chinese Medicine cohort with 37 patients.
The researchers identified five independent predictors: age, marital status, Ann Arbor Stage, B symptoms, and histologic type. Good performance was seen in discrimination and calibration; in the training, internal validation, and external validation cohorts, the C-indices were 0.772, 0.763, and 0.851, respectively. The nomogram was indicated to be accurate based on the calibration curve; a decision curve analysis showed high clinical application value for the nomogram. Using area under the receiver operating characteristic curve values, the prediction accuracy of the nomogram was higher than that of Ann Arbor Stage (0.804 versus 0.630, 0.800 versus 0.637, and 0.811 versus 0.598 for the training, internal validation, and external validation cohorts, respectively).
“Compared with the Ann Arbor Stage, the proposed nomogram showed superior performance in identification, calibration, and clinical guidance,” the authors write.
Copyright © 2021 HealthDay. All rights reserved.